Lexeo Therapeutics (LXEO) EPS (Weighted Average and Diluted) (2022 - 2026)
Lexeo Therapeutics recorded quarterly EPS (Weighted Average and Diluted) of -$0.25 in Q1 2026, down 78.57% quarter-over-quarter from -$0.14 in Q4 2025, and up 74.75% year-over-year from -$0.14 in Q1 2025.
Lexeo Therapeutics' EPS (Weighted Average and Diluted) history runs 5 years deep, the most recent figure standing at -$0.25 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 74.75% year-over-year to -$0.25; the TTM figure through Mar 2026 stood at -$1.32 (up 60.0% YoY), while the FY2025 annual figure was -$1.86, up 39.81% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.25 for Q1 2026 at Lexeo Therapeutics, down from -$0.14 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $19.84 in Q4 2023 to a low of -$12.36 in Q3 2023.
- A 5-year average of -$2.47 and a median of -$0.78 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) jumped 323.93% in 2023 and slumped 103.93% in 2024, its largest moves.
- Lexeo Therapeutics' EPS (Weighted Average and Diluted) stood at -$8.86 in 2022, then surged by 323.93% to $19.84 in 2023, then plunged by 103.93% to -$0.78 in 2024, then soared by 82.05% to -$0.14 in 2025, then sank by 78.57% to -$0.25 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.25, -$0.14, and -$0.33 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - | -0.25 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.25 |
| Dec 31, 2025 | -0.14 |
| Sep 30, 2025 | -0.33 |
| Jun 30, 2025 | -0.60 |
| Mar 31, 2025 | -0.99 |
| Dec 31, 2024 | -0.78 |
| Sep 30, 2024 | -0.89 |
| Jun 30, 2024 | -0.64 |
| Mar 31, 2024 | -0.77 |
| Dec 31, 2023 | 19.84 |
| Sep 30, 2023 | -12.36 |
| Jun 30, 2023 | -8.30 |
| Mar 31, 2023 | -11.58 |
| Dec 31, 2022 | -8.86 |
| Sep 30, 2022 | -10.38 |